Bempedoic acid is protected by several patents related to its composition and method of use. These patents are crucial for the drug's market exclusivity and revenue generation.
When does the main Bempedoic Acid patent expire?
The primary patent covering bempedoic acid, U.S. Patent No. 8,232,270, is set to expire in 2030. This patent specifically claims the chemical compound bempedoic acid itself. [1]
What other patents protect Bempedoic Acid?
Beyond the compound patent, there are other patents covering the drug. For instance, U.S. Patent No. 9,309,245, which is related to the use of bempedoic acid, is set to expire in 2033. [1] Information on other related patents and their expiration dates can be found on DrugPatentWatch.com. [2]
Can generic versions of Bempedoic Acid be launched before patent expiry?
Generally, generic versions of a drug cannot be launched until all relevant patents expire, unless those patents are successfully challenged or invalidated. The expiration dates of the patents, particularly the compound patent expiring in 2030, indicate a potential timeline for generic competition.
What happens if bempedoic acid patents are challenged?
Patent challenges, often filed by generic drug manufacturers, can lead to early termination of patent protection, allowing for the earlier introduction of generic alternatives. The success of such challenges depends on legal arguments regarding patent validity, inventorship, and prior art. Litigation outcomes can significantly alter the market exclusivity period.
Who are the key players and competitors in the Bempedoic Acid market?
Bempedoic acid is marketed by Esperion Therapeutics, Inc. under the brand names Nexletol (for cholesterol lowering) and Nexlizet (a combination with ezetimibe). [3] The emergence of generic versions following patent expiry will likely introduce competition from other pharmaceutical companies.
What is the clinical use of Bempedoic Acid?
Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor used to lower LDL cholesterol. It is prescribed for adults with primary hyperlipidemia or atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C when treated with statins or when statins are not tolerated. [3]
What are the risks associated with Bempedoic Acid?
Common side effects associated with bempedoic acid include hyperuricemia, anemia, increased blood creatinine, and elevated liver enzymes. [3] Patients and healthcare providers should monitor for these potential adverse effects.